12:00 AM
 | 
Apr 29, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ALS-2200: Additional Phase I data

Data from a cohort of 8 treatment-naïve patients with chronic HCV genotype 3 or 4 infection in a double-blind, placebo-controlled, international Phase I trial showed that once-daily 200 mg VX-135 as monotherapy reduced median HCV RNA levels by 4.65 log10 IU/mL from baseline to day 7. Additionally, 5 patients in the cohort achieved HCV RNA levels below the limit of quantification (<=25 IU/mL). One treatment-naïve patient with chronic HCV genotype 2 infection achieved a median reduction in HCV RNA levels of 5.04 log10 IU/mL from baseline...

Read the full 409 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >